Big News: FDA Is Removing Black Box Warnings on Menopause Hormone Therapy

Danielle Melvin N.D. guest author

The FDA has announced it will remove the black box warnings from many menopause hormone therapy (MHT) products. These were the strongest warnings a medication could carry — and for more than 20 years, they shaped how women and clinicians thought about hormone therapy.

Why the Change?

The old warnings came from early 2000s research (the Women’s Health Initiative) that suggested menopause hormone therapy increased risks for heart disease, stroke, blood clots, and breast cancer. But newer evidence shows the story is more nuanced:

• Risks differ by age, how long since menopause, type of hormone, and route of administration.
• Starting HRT within 10 years of menopause or before age 60 carries a much more favorable risk–benefit balance.
• Many women who could benefit were avoiding therapy because of outdated, overly broad warnings.
• The breast cancer risk is not increased with estrogen only, and only a very slight increase with estrogen and progestin after 3 years of use

What’s Actually Changing?

• The FDA will remove black box warnings related to cardiovascular disease, stroke, breast cancer, and dementia for most systemic MHT products.
• The warning for endometrial cancer in estrogen-only therapy for women with a uterus will remain.
• Labels will emphasize individualized decision-making, not one-size-fits-all rules.

What This Means for Women

• Hormone therapy may become more accessible and less stigmatized.
• It does not mean MHT is risk-free — it means decisions should be personalized.
• The “timing matters” message is key: benefits and risks look different for a woman 52 years old in early menopause vs. a woman 68 starting for the first time.
• There are many options for systemic estrogen therapy (patches, pills, creams, vaginal estrogen), each with different risk profiles.
• Vaginal/vulvar estrogen that is dosed for only local effects of vulvar/vaginal dryness, discomfort, itching, recurring urinary tract infections or urinary incontinence does not increase the risk of cardiovascular disease, strokes, clots, breast cancer or endometrial cancer

Bottom Line

This is a major shift toward updated, evidence-based, individualized care. If you’re struggling with menopause symptoms or previously avoided hormone therapy because of scary labels, now is a good time to talk with your clinician about what’s right for you.

Clinicians at A Woman’s Time are well informed and have expert skills in assessing, prescribing, and managing options for perimenopausal and menopausal women – hormonal and non-hormonal.

Resources:

Makary, M. A., Nguyen, C. P., Høeg, T. B., & Tidmarsh, G. F. (2025). Updated Labeling for Menopausal Hormone Therapy. JAMA.

U.S. Department of Health and Human Services. (2025, November 10). Fact sheet: FDA initiates removal of “black box” warnings from menopausal hormone replacement therapy products.